A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer

Cancer

Volumn 121, Issue 11, 2015, Pages 1785-1792

  Graham, Donna M ^a   Isaranuwatchai, Wanrudee ^b   Habbous, Steven ^a   De Oliveira, Claire ^c   Liu, Geoffrey ^a   Siu, Lillian L ^a   Hoch, Jeffrey S ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

computer methods and models; economic issues and research treatment; head and neck cancer; mathematical methods and models; statistical methods and models

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANADA; CANCER INCIDENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG UPTAKE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; INFECTION RATE; MALE; MOUTH INFECTION; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VACCINATION; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROBABILITY; STATISTICAL MODEL; VIROLOGY;

CANADA; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; HUMANS; MALE; MARKOV CHAINS; MODELS, STATISTICAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84929655735     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29111     Document Type: Article

References (63)

1. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-1927.
2. Kjaer SK, Sigurdsson K, Iversen OE, et al., A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res. 2009; 2: 868-878.
3. Garland SM, Hernandez-Avila M, Wheeler CM, et al., Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928-1943.
4. Fairley CK, Hocking JS, Gurrin LC, et al., Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009; 85: 499-502.
5. Donovan B, Franklin N, Guy R, et al., Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011; 11: 39-44.
6. Brotherton J, Gertig D, Chappell G, et al., Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Commun Dis Intell Q Rep. 2011; 35: 197-201.
7. Shearer BD,. HPV vaccination: understanding the impact on HPV disease. National Collaborating Center for Infectious Diseases Purple Paper, Issue 34. Winnipeg, Manitoba, Canada: National Collaborating Center for Infectious Diseases; 2011: 1-18.
8. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep. 2013; 62: 591-595.
9. Jemal A, Simard EP, Dorell C, et al., Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105: 175-201.
10. Immunise Australia Program. Human Papillomavirus (HPV): Information about the National Human Papillomavirus (HPV) Vaccination Program funded under the Immunise Australia Program. Available at: http://health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv. Accessed July 25, 2013.
11. Dorleans F, Giambi C, Dematte L, et al., The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey [serial online]. Euro Surveill. 2010; 15: 19730.
12. Sander BB, Rebolj M, Valentiner-Branth P, Lynge E,. Introduction of human papillomavirus vaccination in Nordic countries. Vaccine. 2012; 30: 1425-1433.
13. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al., Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012; 206: 860-866.
14. UK Department of Health. Annual HPV vaccine coverage in England in 2009/2010. Available at: https://www.gov.uk/government/publications/annual-hpv-vaccine-coverage-in-england-in-2009-2010. Accessed June 21, 2013.
15. Information Services Division Scotland. HPV immunisation uptake statistics: HPV immunisation programme-school year 2011/2012. Available at: http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2012-09-25/2012-09-25-HPV-Uptake-Report.pdf ]. Accessed July 25, 2013.
16. Giuliano AR, Palefsky JM, Goldstone S, et al., Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011; 364: 401-411.
17. Palefsky JM, Giuliano AR, Goldstone S, et al., HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365: 1576-1585.
18. Brisson M, Van de Velde N, Boily MC,. Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect. 2011; 87: 41-43.
19. Van de Velde N, Brisson M, Boily MC,. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine. 2010; 28: 5473-5484.
20. Burchell AN, Tellier P, Coutlee F, Hanley J, Franco EL,. The effect of HPV vaccination on infection in partnerships. Paper presented at: European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference; Monte Carlo; February 17-20, 2010. Abstract SS18-2.
21. Johnson-Obaseki S, McDonald JT, Corsten M, Rourke R,. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg. 2012; 147: 74-78.
22. Reddy VM, Cundall-Curry D, Bridger MW,. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl. 2010; 92: 655-659.
23. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-4301.
24. Blomberg M, Nielsen A, Munk C, Kjaer SK,. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer. 2011; 129: 733-741.
25. Ioka A, Tsukuma H, Ajiki W, Oshima A,. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol. 2005; 35: 45-47.
26. Elbasha EH, Dasbach EJ,. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010; 28: 6858-6867.
27. Kim JJ, Goldie SJ,. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States [serial online]. BMJ. 2009; 339: b3884.
28. Bresse X, Goergen C, Prager, B,., Joura, E,. Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis. Exp Rev Pharmacoecon Outcomes Res. 2014; 14: 269-281.
29. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE,. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011; 29: 8443-8450.
30. National Advisory Committee on Immunization (NACI). NACI statement on human pappillomavirus vaccine. Can Commun Dis Rep. 2007; 33 (ACS-0000): 1-32.
31. Centers for Disease Control and Prevention (CDC). Human papillomavirus-associated cancers-United States, 2004-2008. MMWR Morb Mortal Weekly Rep. 2012; 20: 258-261.
32. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2006.
33. Habbous S, Chu KP, Qiu X, et al., The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a comprehensive cancer centre. Cancer Epidemiol. 2013; 37: 820-829.
34. Habbous S, Harland LT, La Delfa A, et al., Comorbidity and prognosis in head and neck cancers: differences by subsite, stage, and human papillomavirus status. Head Neck. 2014; 36: 802-810.
35. de Oliveira C, Bremner KE, Pataky R, et al., Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study [serial online]. CMAJ Open. 2013; 1: E1-E8.
36. de Oliveira C, Bremner KE, Pataky R, et al., Phase-specific and lifetime costs of cancer in British Columbia and Ontario. Paper presented at: Canadian Association of Health Services and Policy Research Annual Conference; May 28-13, 2013; Vancouver, British Columbia, Canada.
37. Gillison ML, Broutian T, Pickard RK, et al., Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012; 307: 693-703.
38. Liberato NL, Rognoni C, Rubrichi S, et al., Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. Ann Oncol. 2012; 23: 1825-1832.
39. Statistics Canada, Health Statistics Division, Vital Statistics. Probability of dying by age and sex, Canada 2007. Available at: http://www.statcan.gc.ca/pub/91-209-x/2011001/article/11524/figures/desc/desc03-eng.htm. Accessed July 20, 2013.
40. City of Toronto. Human Papillomavirus (HPV) Vaccine for Grade 8 Girls: 2012. Available at: http://www.toronto.ca/health/cdc/factsheets/hpv-vaccine-factsheet.htm-8. Accessed July 20, 2013.
41. Yong JH, Beca J, O'Sullivan B, et al., Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol. 2012; 24: 532-538.
42. Ackerstaff AH, Balm AJ, Rasch CR, et al., First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck. 2009; 31: 77-84.
43. Borggreven PA, Aaronson NK, Verdonck-de Leeuw IM, et al., Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap. Oral Oncol. 2007; 43: 1034-1042.
44. Hannouf MB, Sehgal C, Cao JQ, et al., Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer [serial online]. PLoS One. 2012; 7: e38557.
45. Kreimer AR, Pierce Campbell CM, Lin HY, et al., Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013; 382: 877-887.
46. Moscicki AB, Schiffman M, Burchell A, et al., Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012; 30 (suppl 5): F24-F33.
47. Begum S, Cao D, Gillison M, et al., Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005; 11: 5694-5699.
48. Kreimer AR, Villa A, Nyitray AG, et al., The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev. 2011; 20: 172-182.
49. Statistics Canada. Age Groups and Sex for the Population of Canada, Provinces, Territories, Economic Regions, 2011 Census. 2011 Census of Canada: Topic-Based Tabulations. Available at: http://www12.statcan.gc.ca/census-recensement/2011/dp-pd/tbt-tt/Rp-eng.cfm. Accessed July 20, 2013.
50. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
51. Shi W, Kato H, Perez-Ordonez B, et al., Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009; 27: 6213-6221.
52. Pulte D, Brenner H,. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010; 15: 994-1001.
53. Drummond MF, Sculpher M, Torrance G, et al., Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, New York: Oxford University Press; 2005.
54. Block SL, Nolan T, Sattler C, et al., Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118: 2135-2145.
55. Abendstein H, Nordgren M, Boysen M, et al., Quality of life and head and neck cancer: a 5 year prospective study. Laryngoscope. 2005; 115: 2183-2192.
56. Verdonck-de Leeuw IM, van Bleek WJ, Leemans CR, et al., Employment and return to work in head and neck cancer survivors. Oral Oncol. 2010; 46: 56-60.
57. Jacobson JJ, Epstein JB, Eichmiller FC, et al., The cost burden of oral, oral pharyngeal, and salivary gland cancers in 3 groups: commercial insurance, Medicare, and Medicaid [serial online]. Head Neck Oncol. 2012; 4: 15.
58. Global Alliance for Vaccines and Immunisation (GAVI Alliance). Human papillomavirus vaccine support: record low price agreed for HPV vaccines. Available at: http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/. Accessed October 8, 2013.
59. Herrero R, Quint W, Hildesheim A, et al., Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica [serial online]. PLoS One. 2013; 8: e68329.
60. D'Souza G, Kreimer AR, Viscidi R, et al., Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356: 1944-1956.
61. Brisson M, Van de Velde N, De Wals P, Boily MC,. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007; 25: 5399-5408.
62. Heiligenberg M, Michael KM, Kramer MA, et al., Seroprevalence and determinants of 8 high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sex Transm Dis. 2010; 37: 672-680.
63. Briggs AH, Claxton K, Sculpher MJ,. Decision Modelling for Health Economic Evaluation. Oxford, New York: Oxford University Press; 2006.